Compounds > procaine
Page last updated: 2024-11-03

procaine and Heart Valve Diseases

procaine has been researched along with Heart Valve Diseases in 10 studies

Procaine: A local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1016).
procaine : A benzoate ester, formally the result of esterification of 4-aminobenzoic acid with 2-diethylaminoethanol but formed experimentally by reaction of ethyl 4-aminobenzoate with 2-diethylaminoethanol.

Heart Valve Diseases: Pathological conditions involving any of the various HEART VALVES and the associated structures (PAPILLARY MUSCLES and CHORDAE TENDINEAE).

Research Excerpts

ExcerptRelevanceReference
" The effect of two cardioplegic solution was evaluated by postoperative cardiac function (CI, %SF), released enzymes (CPK), histology and dosage of catecholamine."1.29[Efficacy of myocardial preservation using HTK solution in continuous 120 min cross-clamping method--a comparative study with GIK method]. ( Bonkohara, Y; Hachida, M; Imamaki, M; Katsumata, T; Koyanagi, H; Nemoto, S; Nonoyama, M; Saitou, S; Satou, M; Toyama, A, 1993)
"Procaine infusion was started after intubation during steady-state anaesthesia, and continued until start of cardiopulmonary by-pass."1.27Haemodynamic effects of intravenous procaine as a supplement to general anaesthesia in patients with valvular heart disease. ( Flachs, H; Skovsted, P; Sørensen, O; Waaben, J; Wiberg-Jørgensen, F, 1984)

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19904 (40.00)18.7374
1990's1 (10.00)18.2507
2000's2 (20.00)29.6817
2010's2 (20.00)24.3611
2020's1 (10.00)2.80

Authors

AuthorsStudies
Duan, L1
Hu, GH1
Wang, E1
Zhang, CL1
Huang, LJ1
Duan, YY1
Gaudino, M1
Pragliola, C1
Anselmi, A1
Pieroni, M1
De Paulis, S1
Leone, A1
De Caterina, AR1
Massetti, M1
Matzelle, SJ1
Murphy, MJ1
Weightman, WM1
Gibbs, NM1
Edelman, JJ1
Passage, J1
Uchikawa, S1
Aomi, S1
Kawai, A1
Yamazaki, K1
Tomizawa, Y1
Nishida, H1
Endo, M1
Koyanagi, H2
Savini, C1
Camurri, N1
Castelli, A1
Dell'Amore, A1
Pacini, D1
Suarez, SM1
Grillone, G1
Di Bartolomeo, R1
Waaben, J1
Sørensen, O1
Wiberg-Jørgensen, F1
Flachs, H1
Skovsted, P1
Dragoĭchev, Ch2
Daskalov, E2
Konstantinov, P2
Madzharov, D1
Hachida, M1
Bonkohara, Y1
Nonoyama, M1
Toyama, A1
Saitou, S1
Nemoto, S1
Satou, M1
Katsumata, T1
Imamaki, M1
Dimitrov, D1
Madzharov, M1
Fenchel, G1
Seybold-Epting, W1
Huth, C1
Hoffmeister, HE1
Stunkat, R1
Heller, W1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Custodiol-HTK Solution as a Cardioplegic Agent- A Prospective Non-Inferiority Randomized Clinical Trial[NCT01681095]Phase 2110 participants (Actual)Interventional2012-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

All Cause Mortality

Number of participants with all-cause mortality AS reported in the Society of Thoracic Surgeons (STS) database after 30 days postoperative (NCT01681095)
Timeframe: 30 days post procedure

Interventionparticipants (Number)
Cardioplegia: Custodiol HTK Solution0
Cold Blood Cardioplegia0

Biochemical Marker - Creatine Kinase MB Isoenzyme (CK-MB)

CK-MB measured 24 hours post-operatively (NCT01681095)
Timeframe: 24 hours post procedure

Interventionng/mL (Mean)
Cardioplegia: Custodiol HTK Solution20
Cold Blood Cardioplegia24

Biochemical Marker - Creatine Kinase MB Isoenzyme (CK-MB)

CK-MB measured 48 hours post-operatively (NCT01681095)
Timeframe: 48 hours post procedure

Interventionng/mL (Mean)
Cardioplegia: Custodiol HTK Solution6.0
Cold Blood Cardioplegia7.8

Biochemical Marker - Creatine Kinase MB Isoenzyme (CK-MB)

CK-MB measured pre-operatively (NCT01681095)
Timeframe: pre-operative

Interventionng/mL (Mean)
Cardioplegia: Custodiol HTK Solution1.9
Cold Blood Cardioplegia2.6

Cardiac Dysrhythmias

Number of participants with new or worsening of cardiac dysrhythmias (NCT01681095)
Timeframe: up to 36 hrs post surgery

Interventionparticipants (Number)
Cardioplegia: Custodiol HTK Solution24
Cold Blood Cardioplegia30

Cardiac Marker - Troponin-I

Troponin-I measured 24 hours post-operative (NCT01681095)
Timeframe: 24 hours post procedure

Interventionng/mL (Mean)
Cardioplegia: Custodiol HTK Solution5.7
Cold Blood Cardioplegia7.8

Cardiac Marker - Troponin-I

Troponin-I measured 48 hours post-operative (NCT01681095)
Timeframe: 48 hours post procedure

Interventionng/mL (Mean)
Cardioplegia: Custodiol HTK Solution3.0
Cold Blood Cardioplegia4.8

Cardiac Marker - Troponin-I

Troponin-I measured pre-operatively (NCT01681095)
Timeframe: pre-operatively

Interventionng/mL (Mean)
Cardioplegia: Custodiol HTK Solution.03
Cold Blood Cardioplegia.03

Cardiovascular Mortality

Number of participants with cardiovascular-related mortality AS reported in the Society of Thoracic Surgeons (STS) database after 30 days postoperative (NCT01681095)
Timeframe: 30 days post procedure

Interventionparticipants (Number)
Cardioplegia: Custodiol HTK Solution0
Cold Blood Cardioplegia0

Change in Creatine Phosphokinase-MB Isoenzyme (CK-MB)

Creatine phosphokinase MB isoenzyme (CK-MB) difference from baseline 7 hours post surgery (NCT01681095)
Timeframe: Baseline and 7 hours post surgery

Interventionng/mL (Median)
Cardioplegia: Custodiol HTK Solution18.8
Cold Blood Cardioplegia22.2

Change in Troponin I

Troponin I values, difference from baseline 7 hours post surgery (NCT01681095)
Timeframe: Baseline and 7 hours post surgery

Interventionng/mL (Median)
Cardioplegia: Custodiol HTK Solution9.65
Cold Blood Cardioplegia10.15

Changes in Left Ventricular (LV) Ejection Fraction (EF) by Transthoracic Echocardiogram (TTE)

LV ejection fraction by TTE, difference from baseline at 24 hours post surgery (NCT01681095)
Timeframe: Baseline and 24 hours post surgery

Intervention% LV volume (Mean)
Cardioplegia: Custodiol HTK Solution-0.06
Cold Blood Cardioplegia1.9

Duration of Vasopressor / Inotropic Agent

Total time in minutes on any vasopressor or inotropic agent, including norepinephrine, epinephrine, vasopressin, milrinone, dobutamine, dopamine and/or neo-synephrine (NCT01681095)
Timeframe: up to 36 hours post procedure

Interventionminutes (Median)
Cardioplegia: Custodiol HTK Solution340
Cold Blood Cardioplegia582

Intensive Care Unit (ICU) Length of Stay

Duration of stay in ICU, from ICU admission to ICU discharge (NCT01681095)
Timeframe: up to 100 days after admission

Interventiondays (Median)
Cardioplegia: Custodiol HTK Solution3
Cold Blood Cardioplegia3

Myocardial Infarction

Number or participants fulfilling at least two of the following 3 criteria: (1) CK-MB of 100 ug/L or more and/or troponin-I of 3.0 ug/L or more, (2) appearance of new postoperative Q waves on the EKG of more than 0.03 seconds, and (3) a new hypokinetic or akinetic area in the left or right ventricle by echocardiography. (NCT01681095)
Timeframe: up to 36 hours post procedure

Interventionparticipants (Number)
Cardioplegia: Custodiol HTK Solution0
Cold Blood Cardioplegia0

Postoperative Inotropic Infusion >20 Minutes

Number of patients receiving vasopressor or inotropic infusion for greater than 20 minutes in the operating room, including norepinephrine, epinephrine, vasopressin, milrinone, dobutamine, dopamine and/or neo-synephrine. (NCT01681095)
Timeframe: during operative procedure

Interventionparticipants (Number)
Cardioplegia: Custodiol HTK Solution47
Cold Blood Cardioplegia43

Time on Mechanically Assisted Ventilation

time in hours from intubation to extubation, with intervening transport to the cardiac critical care unit. (NCT01681095)
Timeframe: up to 36 hours post procedure

Interventionhours (Median)
Cardioplegia: Custodiol HTK Solution10.5
Cold Blood Cardioplegia11.4

Trials

1 trial available for procaine and Heart Valve Diseases

ArticleYear
Randomized trial of HTK versus warm blood cardioplegia for right ventricular protection in mitral surgery.
    Scandinavian cardiovascular journal : SCJ, 2013, Volume: 47, Issue:6

    Topics: Aged; Cardiac Surgical Procedures; Cardioplegic Solutions; Female; Glucose; Heart Arrest, Induced; H

2013

Other Studies

9 other studies available for procaine and Heart Valve Diseases

ArticleYear
Del Nido versus HTK cardioplegia for myocardial protection during adult complex valve surgery: a retrospective study.
    BMC cardiovascular disorders, 2021, 12-18, Volume: 21, Issue:1

    Topics: Adolescent; Adult; Aged; Cardiac Surgical Procedures; Electrolytes; Female; Glucose; Heart Arrest, I

2021
Minimally invasive mitral valve surgery using single dose antegrade Custodiol cardioplegia.
    Heart, lung & circulation, 2014, Volume: 23, Issue:9

    Topics: Adult; Aged; Blood Transfusion; Cardioplegic Solutions; Cardiotonic Agents; Female; Glucose; Heart A

2014
Left ventricular mass index reduction early after an isolated aortic valve replacement with St. Jude Medical 19A-HP.
    The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi, 2003, Volume: 51, Issue:8

    Topics: Aged; Aortic Valve; Female; Glucose; Heart Valve Diseases; Heart Valve Prosthesis Implantation; Hear

2003
Myocardial protection using HTK solution in minimally invasive mitral valve surgery.
    The heart surgery forum, 2005, Volume: 8, Issue:1

    Topics: Aged; Cardioplegic Solutions; Cardiopulmonary Bypass; Constriction; Creatine Kinase; Creatine Kinase

2005
Haemodynamic effects of intravenous procaine as a supplement to general anaesthesia in patients with valvular heart disease.
    Acta anaesthesiologica Scandinavica, 1984, Volume: 28, Issue:1

    Topics: Adjuvants, Anesthesia; Anesthesia, General; Blood Pressure; Cardiac Output; Heart Rate; Heart Valve

1984
[Initial results of using Cardioplegin in heart operations].
    Khirurgiia, 1981, Volume: 34, Issue:1

    Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Aspartic Acid; Child; Child, Preschool; Drug Combinations

1981
[Efficacy of myocardial preservation using HTK solution in continuous 120 min cross-clamping method--a comparative study with GIK method].
    [Zasshi] [Journal]. Nihon Kyobu Geka Gakkai, 1993, Volume: 41, Issue:9

    Topics: Cardioplegic Solutions; Evaluation Studies as Topic; Glucose; Heart Arrest, Induced; Heart Valve Dis

1993
[Chemical cardioplegia in prosthesis of the aortic valve].
    Khirurgiia, 1979, Volume: 32, Issue:4

    Topics: Adolescent; Adult; Aortic Valve; Aspartic Acid; Child; Drug Combinations; Drug Evaluation; Extracorp

1979
[Behaviour of ATP and lactate in human papillary muscle during profound hypothermia and injection cardioplegia with magnesium-asparatate-procaine (author's transl)].
    Thoraxchirurgie, vaskulare Chirurgie, 1978, Volume: 26, Issue:6

    Topics: Adenosine Triphosphate; Cardiac Output; Coronary Vessels; Heart; Heart Arrest, Induced; Heart Valve

1978